AR117435A1 - Derivados de oxopiridina sustituidos - Google Patents
Derivados de oxopiridina sustituidosInfo
- Publication number
- AR117435A1 AR117435A1 ARP190103745A ARP190103745A AR117435A1 AR 117435 A1 AR117435 A1 AR 117435A1 AR P190103745 A ARP190103745 A AR P190103745A AR P190103745 A ARP190103745 A AR P190103745A AR 117435 A1 AR117435 A1 AR 117435A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- represents hydrogen
- group
- difluoromethyl
- fluorine
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 16
- 239000001257 hydrogen Substances 0.000 abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 abstract 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 14
- -1 tetrahydro-2H-pyran-2-yl Chemical group 0.000 abstract 7
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 6
- 229910052731 fluorine Inorganic materials 0.000 abstract 6
- 239000011737 fluorine Substances 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Chemical group 0.000 abstract 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 2
- 230000009424 thromboembolic effect Effects 0.000 abstract 2
- 230000001732 thrombotic effect Effects 0.000 abstract 2
- KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical group C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- SYGWYBOJXOGMRU-UHFFFAOYSA-N chembl233051 Chemical group C1=CC=C2C3=CC(C(N(CCN(C)C)C4=O)=O)=C5C4=CC=CC5=C3SC2=C1 SYGWYBOJXOGMRU-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 abstract 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical group FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117435A1 true AR117435A1 (es) | 2021-08-04 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103745A AR117435A1 (es) | 2018-12-21 | 2019-12-18 | Derivados de oxopiridina sustituidos |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (fr) |
| JP (1) | JP2022514303A (fr) |
| KR (1) | KR20210106504A (fr) |
| CN (1) | CN113474348A (fr) |
| AR (1) | AR117435A1 (fr) |
| AU (1) | AU2019407909B2 (fr) |
| BR (1) | BR112021009435A2 (fr) |
| CA (1) | CA3124220A1 (fr) |
| CL (1) | CL2021001613A1 (fr) |
| CO (1) | CO2021007908A2 (fr) |
| CR (1) | CR20210342A (fr) |
| DO (1) | DOP2021000128A (fr) |
| EA (1) | EA202191764A1 (fr) |
| EC (1) | ECSP21043895A (fr) |
| IL (1) | IL283990A (fr) |
| JO (1) | JOP20210161A1 (fr) |
| MA (1) | MA54521A (fr) |
| MX (1) | MX2021007508A (fr) |
| PE (1) | PE20211790A1 (fr) |
| SG (1) | SG11202104384PA (fr) |
| TW (1) | TW202039510A (fr) |
| WO (1) | WO2020127504A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102807521B1 (ko) * | 2018-03-15 | 2025-05-16 | 바이엘 악티엔게젤샤프트 | 2종의 4-｛[(2s)-2-｛4-[5-클로로-2-(1h-1,2,3-트리아졸-1-일)페닐]-5-메톡시-2-옥소피리딘-1(2h)-일}부타노일]아미노}-2-플루오로벤즈아미드 유도체의 제조 방법 |
| CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
| GEAP202316370A (en) | 2021-03-09 | 2023-11-27 | Bayer Ag | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3] triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide |
| WO2022189280A1 (fr) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| MX2023010614A (es) | 2021-03-09 | 2023-09-19 | Bayer Ag | Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida. |
| CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
| EP4716732A1 (fr) * | 2023-04-28 | 2026-04-01 | Basf Se | Utilisation de 4-alcoxypentanoates d'alkyle comme arômes chimiques |
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| US9475809B2 (en) | 2013-07-23 | 2016-10-25 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| WO2015063093A1 (fr) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substituée |
| WO2016046166A1 (fr) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| WO2016046158A1 (fr) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| JP6517925B2 (ja) | 2014-09-24 | 2019-05-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたオキソピリジン誘導体 |
| WO2016046156A1 (fr) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| ES2716417T3 (es) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica |
| ES2712886T3 (es) * | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
| CA2979937A1 (fr) | 2015-03-19 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Derives d'oxopyridine comme inhibiteurs du facteur xia pour le traitement de la thrombose |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| EP3344618A1 (fr) | 2015-09-04 | 2018-07-11 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
-
2019
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko not_active Ceased
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/fr not_active Ceased
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/fr not_active Withdrawn
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/fr active Pending
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en not_active Ceased
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA54521A (fr) | 2022-03-30 |
| KR20210106504A (ko) | 2021-08-30 |
| JP2022514303A (ja) | 2022-02-10 |
| CO2021007908A2 (es) | 2021-07-19 |
| BR112021009435A2 (pt) | 2021-08-17 |
| CN113474348A (zh) | 2021-10-01 |
| PE20211790A1 (es) | 2021-09-09 |
| MX2021007508A (es) | 2021-08-05 |
| EP3898633A1 (fr) | 2021-10-27 |
| CR20210342A (es) | 2021-08-09 |
| DOP2021000128A (es) | 2021-09-30 |
| SG11202104384PA (en) | 2021-05-28 |
| CL2021001613A1 (es) | 2021-12-03 |
| AU2019407909B2 (en) | 2023-05-25 |
| AU2019407909A1 (en) | 2021-05-27 |
| CA3124220A1 (fr) | 2020-06-25 |
| JOP20210161A1 (ar) | 2023-01-30 |
| TW202039510A (zh) | 2020-11-01 |
| ECSP21043895A (es) | 2021-07-30 |
| EA202191764A1 (ru) | 2021-10-22 |
| WO2020127504A1 (fr) | 2020-06-25 |
| IL283990A (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098492A1 (es) | Derivados de purina | |
| AR111776A1 (es) | Heteroarilos inhibidores de las proteínas ras mutantes de g12c | |
| AR107488A1 (es) | Compuestos de benzopirazol y análogos de éstos | |
| AR113886A1 (es) | Derivados de indol macrocíclicos | |
| AR105104A1 (es) | Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR111241A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| AR103265A1 (es) | Compuestos de azolina sustituidos con un sistema de anillos condensado | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR113887A1 (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| AR090678A1 (es) | Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis | |
| AR097633A1 (es) | Pesticidas de azol bicíclico sustituido con heterociclos | |
| AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR100879A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
| AR113888A1 (es) | Derivados de indol macrocíclicos sustituidos | |
| AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
| AR097403A1 (es) | Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación | |
| AR104856A1 (es) | Derivados de difluorocetamida | |
| AR101077A1 (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
| AR103192A1 (es) | Isotiazolamidas, procesos para su preparación y su uso como herbicidas y/o reguladores del crecimiento vegetal | |
| AR107512A1 (es) | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 | |
| AR096424A1 (es) | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona | |
| AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
| PE20211790A1 (es) | Derivados de oxopiridina sustituidos | |
| AR124717A1 (es) | Compuestos de derivados sustituidos en 4,6 de ip4 | |
| AR099052A1 (es) | Derivados de azaindol |